Blood Cancer Journal

Molecular signatures of multiple myeloma progression through single cell RNA-Seq

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1

Oprozomib in patients with newly diagnosed multiple myeloma

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases

Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies

Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors

Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells

World Health Organization class-independent risk categorization in mastocytosis

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing

Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma

Validation of the Mayo alliance prognostic system for mastocytosis

Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees

Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma

The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia